摘要
来源于山羊豆的一种天然产物,二甲双胍盐酸盐,是现在二型糖尿病治疗管理前沿中的一种口服药物。近几十年来,一系列的临床观察表明二甲双胍盐酸盐能降低糖尿病病人癌症发展的风险,还能增强某些类型恶性肿瘤的治疗应答和个体生存率。此外,许多体内外预临床数据表明二甲双胍盐酸盐通过介导一系列机制,确实具有抗肿瘤细胞增殖能力。有趣的是,二甲双胍盐酸盐被证明能与某些抗肿瘤药物产生协同作用,也能克服多种肿瘤的化学和放射耐药性,这一发现为抗肿瘤发生与发展的新型治疗战略提供了一个有希望的基础理论。然而,因为现有数据所存在的显著矛盾,这个理论始终存在争议。预临床研究的局限性和流行性病学的注意事项,与此同时还有各种癌症之间的显著差异以及基本未知的二甲双胍盐酸盐作用模式,使得纵向调查的施展迫在眉睫。如今,大量的大型临床试验正在全球范围内进行,来确定二甲双胍盐酸盐在各种人类癌症中预防和预后的作用。如果有好的结果出现,那么二甲双胍盐酸盐将会成为人体肿瘤管理中一种有吸引力的辅助候选药,因其安全性,耐药性和低成本,有望能减少现在抗癌疗法的副作用和零相应参数,从而提高癌症患者的生活质量和生存率。
关键词: 二甲双胍盐酸盐,辅助药物,抗癌药剂,化学疗法,放射治疗,临床试验
Current Medicinal Chemistry
Title:Metformin and Anti-Cancer Therapeutics: Hopes for a More Enhanced Armamentarium Against Human Neoplasias?
Volume: 24 Issue: 1
Author(s): Maria-Ioanna Christodoulou, Andreas Scorilas.
Affiliation:
关键词: 二甲双胍盐酸盐,辅助药物,抗癌药剂,化学疗法,放射治疗,临床试验
摘要: Metformin, a natural product from Galega officinalis, is an oral drug, now in the forefront of the therapeutic management of type-2 diabetes mellitus. A series of clinical observations of the last decades, support that metformin may contribute to lowering the risk of cancer development in diabetic patients, and also to improvement of response-to-therapy and survival in individuals with certain types of malignancies. Moreover, several preclinical in vitro and in vivo data indicate that metformin indeed exerts anti-proliferative capacities upon tumor cells mediated through a variety of mechanisms. Interestingly, metformin has been shown to act in synergy with certain anti-cancer agents and also to overcome chemo- and/or radio-resistance of various types of tumors, providing a hopeful rationale for novel therapeutic strategies against cancer development and progression. However, this remains an issue of controversy, since significant contradictions exist among the available data. Limitations of preclinical studies and caveats of epidemiological works, together with significant variances among the several types of cancer and the fact that the mode of metformin’s action is largely unknown, make longitudinal surveys urgently needed. Now, a plethora of large clinical trials are active worldwide, aiming at determining the effect of metformin in the prevention or prognosis of a variety of human cancers. If encouraging results arise, metformin will be an attractive candidate adjuvant in the management of human neoplasias, due to its safety, tolerability and low-cost, expected to mitigate adverse effects and no-response parameters of current anti-cancer therapeutics, thus improving the quality of life and survival of cancer patients.
Export Options
About this article
Cite this article as:
Maria-Ioanna Christodoulou, Andreas Scorilas. , Metformin and Anti-Cancer Therapeutics: Hopes for a More Enhanced Armamentarium Against Human Neoplasias?, Current Medicinal Chemistry 2017; 24 (1) . https://dx.doi.org/10.2174/0929867323666160907161459
DOI https://dx.doi.org/10.2174/0929867323666160907161459 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Heat Shock Protein-60 and Risk for Cardiovascular Disease
Current Pharmaceutical Design Visceral Adipose Tissue and Atherosclerosis
Current Vascular Pharmacology Oxytocin - A Multifunctional Analgesic for Chronic Deep Tissue Pain
Current Pharmaceutical Design Half-Life of Sulfonylureas in HNF1A and HNF4A Human MODY Patients is not Prolonged as Suggested by the Mouse Hnf1a<sup>-/-</sup> Model
Current Pharmaceutical Design Circulating Endothelial Progenitor Cells Characterization, Function and Relationship with Cardiovascular Risk Factors
Current Pharmaceutical Design Diabetes Therapy: Novel Patents Targeting the Glucose-Induced Insulin Secretion
Recent Patents on DNA & Gene Sequences New Player on An Old Field; the Keap1/Nrf2 Pathway as a Target for Treatment of Type 2 Diabetes and Metabolic Syndrome
Current Diabetes Reviews Therapeutic Progress and Knowledge Basis on the Natriuretic Peptide System in Heart Failure
Current Topics in Medicinal Chemistry Endocrine Disruptors and Human Health
Mini-Reviews in Medicinal Chemistry Immune-Mediated Mechanisms in Atherosclerosis: Prevention and Treatment of Clinical Manifestations
Current Pharmaceutical Design Mitochondrial Tolerance to Drugs and Toxic Agents in Ageing and Disease
Current Drug Targets Functional Link Between Adenosine and Insulin: A Hypothesis for Fetoplacental Vascular Endothelial Dysfunction in Gestational Diabetes
Current Vascular Pharmacology Acute Toxicological and Histopathological Elucidation of <i>Rheum emodi</i> Rhizome Extract to Demonstrate Antidiabetic Activity in Alloxan-induced Diabetic Rats
Current Bioactive Compounds Lactic Acidosis, Hypotension, and Sensorineural Hearing Loss Following Intentional Metformin Overdose
Current Drug Safety Micronutrient Intake in the Etiology, Prevention and Treatment of Osteosarcopenic Obesity
Current Aging Science Therapeutic Effects of Renal Denervation on Renal Failure
Current Neurovascular Research Stroke as a Cause of Death in Death Certificates of Patients with Dementia: A Cohort Study from the Swedish Dementia Registry
Current Alzheimer Research Frontier View on Nanotechnological Strategies for Neuro-therapy
Current Drug Metabolism The Role of Endothelial Dysfunction in Aortic Aneurysms
Current Pharmaceutical Design Editorial (Application of a Multidisciplinary Approach to Alzheimers Disease to Develop Novel Drug Targets by Integrating Biomarkers, Imaging, Genetic and Molecular Strategies)
Current Alzheimer Research